Product Information
CLINDAMYCIN (PEDI) 75 MG/5 ML is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1288 per ML under NDC 64980051110. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 28, 2012. Its Orange Book therapeutic-equivalence code is AA.
Strength
75 mg/5mL
Manufacturer
Rising Pharma Holdings Inc.NDC
64980051110
Classification
Generic
Dosage Form
GRANULE, FOR SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLINDAMYCIN PALMITATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA201821FDA Approved
8/28/2012
TE Code
AA
On Market Since
9/11/2012
Pharmacological Classes
Price Statistics
The NADAC for CLINDAMYCIN (PEDI) 75 MG/5 ML has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 69.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1288 per ML |
|---|---|
| All-time high | $0.4399 (Mar 12, 2014) |
| All-time low | $0.1274 (Jul 22, 2026) |
| 52-week high | $0.1693 |
| 52-week low | $0.1274 |
| Median price | $0.2238 |
| Average price | $0.2470 |
| Largest weekly change | +49.2% (Aug 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CLINDAMYCIN PALMITATE HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CLINDAMYCIN PALMITATE HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDAMYCIN (PEDI) 75 MG/5 ML?
The current National Average Drug Acquisition Cost (NADAC) for CLINDAMYCIN (PEDI) 75 MG/5 ML, manufactured by Rising Pharma Holdings Inc., is $0.1288 per ML (NDC 64980051110), effective Sep 30, 2026.
How has the price of CLINDAMYCIN (PEDI) 75 MG/5 ML changed over time?
Over the history we have for it, the NADAC for CLINDAMYCIN (PEDI) 75 MG/5 ML has declined 69.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CLINDAMYCIN (PEDI) 75 MG/5 ML?
Since Nov 28, 2013, the NADAC for CLINDAMYCIN (PEDI) 75 MG/5 ML has ranged from a low of $0.1274 (Jul 22, 2026) to a high of $0.4399 (Mar 12, 2014), with a median of $0.2238 per ML.
Are there cheaper alternatives to CLINDAMYCIN (PEDI) 75 MG/5 ML?
No other NADAC-published product currently shares the active ingredient and strength of CLINDAMYCIN (PEDI) 75 MG/5 ML in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLINDAMYCIN (PEDI) 75 MG/5 ML?
CLINDAMYCIN (PEDI) 75 MG/5 ML (NDC 64980051110) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.